BBA
CRBP icon

Baker Bros. Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Baker Bros. Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,248
Closed -$1.25M – 103
2018
Q2 		$1.25M Sell
8,248
-13,776
-63% -$2.5M 0.01% 102
2018
Q1 		$4.03M Hold
22,024
– – 0.03% 83
2017
Q4 		$4.69M Buy
+22,024
New +$4.71M 0.04% 81
2017
Q3 		– Sell
-4,338
Closed -$820K – 122
2017
Q2 		$820K Hold
4,338
– – 0.01% 105
2017
Q1 		$1.07M Sell
4,338
-4,333
-50% -$1.06M 0.01% 100
2016
Q4 		$2.2M Buy
+8,671
New +$1.99M 0.02% 91

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Baker Bros. Advisors's CRBP Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2018, closing a stake of 8,248 shares — an estimated $1.25M sold.

Baker Bros. Advisors first reported a position in CRBP in Q4 2016 and held it in 6 quarters. The position peaked at $4.69M in Q4 2017. 77 funds tracked by Wall St. Rank hold CRBP as of Q3 2018.

  • Baker Bros. Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 8,248 Corbus Pharmaceuticals shares in Q3 2018, an estimated $1.25M.
  • Baker Bros. Advisors first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 6 quarters.
  • Baker Bros. Advisors's Corbus Pharmaceuticals position peaked at $4.69M in Q4 2017.
  • 77 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.